Overview

Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

Status:
NOT_YET_RECRUITING
Trial end date:
2032-08-01
Target enrollment:
Participant gender:
Summary
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis * with tocilizumab, * while using less cortisone.
Phase:
PHASE3
Details
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Treatments:
Prednisone